Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STANDARD BIOTOOLS INC. Director's Dealing 2024

Mar 7, 2024

32853_dirs_2024-03-06_f9e75518-d071-4b99-b1c2-013a4b3c3512.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2024-03-04

Reporting Person: Casdin Partners Master Fund, L.P. (Director, 10% Owner)
Reporting Person: Casdin Capital, LLC (Director, 10% Owner)
Reporting Person: Casdin Partners GP, LLC (Director, 10% Owner)
Reporting Person: Casdin Private Growth Equity Fund II, L.P. (Director)
Reporting Person: Casdin Private Growth Equity Fund II GP, LLC (Director)
Reporting Person: Casdin Partners FO1-MSV, LP (Director)
Reporting Person: Casdin Private Growth Equity Fund, L.P. (Director)
Reporting Person: CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (Director)
Reporting Person: Casdin Eli (Director, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-03-04 Common Stock P 250000 $2.57 Acquired 11496525 Direct
2024-03-05 Common Stock P 1403 $2.615 Acquired 11497928 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 103556 Direct
Common Stock 2744219 Indirect
Common Stock 1200000 Indirect
Common Stock 7548000 Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F3: The securities are owned directly by Eli Casdin.

F4: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

F5: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

F6: The securities are owned directly by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II.